NEW YORK (GenomeWeb) – In an analysis published in Nature Medicine today, the Broad Institute's David Scott and Feng Zhang said that prescreening patients with whole-genome sequencing and then integrating that information with empirical methods for guide RNA selection could help researchers design CRISPR-based therapeutics that are both efficacious and safe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.